Assessing remission in major depressive disorder and generalized anxiety disorder clinical trials with the discan metric of the Sheehan disability scale

International Clinical Psychopharmacology

Volumn 26, Issue 2, 2011, Pages 75-83

  Sheehan, David V ^a   Harnett Sheehan, Kathy ^a   Spann, Melissa E ^c   Thompson, Harry F ^b   Prakash, Apurva ^b  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b ELI LILLY AND COMPANY   (United States)

^c ALCON RESEARCH LTD   (United States)

Author keywords

anxiety; depression; disability; functional impairment; generalized anxiety disorder; major depressive disorder; remission; Sheehan disability scale

Indexed keywords

DULOXETINE; PLACEBO;

ANXIETY DISORDER; ARTICLE; DISABILITY; DISEASE SEVERITY; DRUG EFFICACY; GENERALIZED ANXIETY DISORDER; HAMILTON ANXIETY SCALE; HAMILTON SCALE; HUMAN; MAJOR DEPRESSION; META ANALYSIS; MONTGOMERY ASBERG DEPRESSION RATING SCALE; MULTICENTER STUDY (TOPIC); PRIORITY JOURNAL; PSYCHOLOGICAL RATING SCALE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; SHEEHAN DISABILITY SCALE; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

ANTIDEPRESSIVE AGENTS; ANXIETY DISORDERS; COMORBIDITY; DEPRESSION; DEPRESSIVE DISORDER, MAJOR; DOUBLE-BLIND METHOD; HUMANS; OUTPATIENTS; PLACEBOS; PSYCHIATRIC STATUS RATING SCALES; PSYCHOMETRICS; THIOPHENES; TIME FACTORS; TREATMENT OUTCOME;

EID: 79951509430     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/YIC.0b013e328341bb5f     Document Type: Article

References (43)

1. American Psychiatric Association (2004). Diagnostic and statistical manual of mental disorders. 4th ed. Washington DC: American Psychiatric Association.
2. Ballenger JC (1999). Clinical guidelines for establishing remission in patients with depression and anxiety. J Clin Psychiatry 60 (Suppl 22):29-34. (Pubitemid 30107953)
3. Bijl RV, Ravelli A (2000). Current and residual functional disability associated with psychopathology: findings from the Netherlands Mental Health Survey and Incidence Study (NEMESIS). Psychol Med 30:657-668. (Pubitemid 30410328)
4. Detke MJ, Wiltse CG, Mallinckrodt CH, McNamara RK, Demitrack MA, Bitter I (2004). Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial. Eur Neuropsychophar-macol 14:457-470. (Pubitemid 39626894)
5. Giller E Jr, Bialos D, Riddle MA, Waldo MC (1988). MAOI treatment response: multiaxial assessment. J Affect Disord 14:171-175. (Pubitemid 18060255)
6. Grant BF, Hasin DS, Stinson FS, Dawson DA, June Ruan W, Goldstein RB, et al. (2005). Prevalence, correlates, co-morbidity, and comparative disability of DSM-IV generalized anxiety disorder in the USA: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Psychol Med 35:1747-1759. (Pubitemid 41672353)
7. Greenberg PE, Kessler RC, Nells TL, Finkelstein SN, Berndt ER (1996). Depression in the workplace: an economic perspective. In: Feighner JP, Boyer WF, editors. Selective serotonin reuptake inhibitors: advances in basic research and clinical practice. New York: Wiley; pp. 327-363.
8. Greenberg PE, Sisitsky T, Kessler RC, Finkelstein SN, Berndt ER, Davidson JR, et al. (1999). The economic burden of anxiety disorders in the 1990s. J Clin Psychiatry 60:427-435. (Pubitemid 29369796)
9. Guy W (1976). The clinician global severity and impression scales. ECDEU assessment manual for psychopharmacology [76-338]. Rockville, MD: US Department of Health, Education, and Welfare. pp. 218-222.
10. Hamilton M (1959). The assessment of anxiety states by rating. Br J Med Psychol 32:50-55.
11. Hamilton M (1960). A rating scale for depression. J Neurol Neurosurg Psychiatry 23:56-62.
12. Hamilton M (1967). Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 6:278-296.
13. Hartford J, Kornstein S, Liebowitz M, Pigott T, Russell J, Detke M, et al. (2007). Duloxetine as an SNRI treatment for generalized anxiety disorder: results from a placebo and active-controlled trial. Int Clin Psychopharmacol 22:167-174. (Pubitemid 46559873)
14. Keller MB (2003). Past, present, and future directions for defining optimal treatment outcome in depression: remission and beyond. JAMA 289:3152-3160. (Pubitemid 37432891)
15. Kelsey JE (2001). Clinician perspective on achieving and maintaining remission in depression. J Clin Psychiatry 62 (Suppl 26):16-21. (Pubitemid 34003370)
16. Kennedy N, Foy K, Sherazi R, McDonough M, McKeon P (2007). Long-term social functioning after depression treated by psychiatrists: a review. Bipolar Disord 9:25-37. (Pubitemid 46671671)
17. Kessler RC, DuPont RL, Berglund P, Wittchen HU (1999). Impairment in pure and comorbid generalized anxiety disorder and major depression at 12 months in two national surveys. Am J Psychiatry 156:1915-1923.
18. Koponen H, Allgulander C, Erickson J, Dunayevich E, Pritchett Y, Detke MJ, et al. (2007). Efficacy of duloxetine for the treatment of generalized anxiety disorder: implications for primary care physicians. Prim Care Companion J Clin Psychiatry 9:100-107. (Pubitemid 46607463)
19. Leon AC, Olfson M, Portera L, Farber L, Sheehan DV (1997). Assessing psychiatric impairment in primary care with the Sheehan Disability Scale. Int J Psychiatry Med 27:93-105. (Pubitemid 27407503)
20. Lipman RS, Covi L, Downing RW, Fisher S, Kahn RJ, McNair DM, et al. (1981). Pharmacotherapy of anxiety and depression: rationale and study design. Psychopharmacol Bull 17:91-94. (Pubitemid 12166141)
21. Miller IW, Keitner GI, Schatzberg AF, Klein DN, Thase ME, Rush AJ, et al. (1998). The treatment of chronic depression, part 3: psychosocial functioning before and after treatment with sertraline or imipramine. J Clin Psychiatry 59:608-619. (Pubitemid 28555422)
22. Mintz J, Mintz LI, Arruda MJ, Hwang SS (1992). Treatments of depression and the functional capacity to work. Arch Gen Psychiatry 49:761-768.
23. Montgomery SA, Asberg M (1979). A new depression scale designed to be sensitive to change. Br J Psychiatry 134:382-389. (Pubitemid 9136500)
24. Murray CJ, Lopez AD (1996). Evidence-based health policy lessons from the Global Burden of Disease Study. Science 274:740-743. (Pubitemid 26398244)
25. Nicolini H, Bakish D, Duenas H, Spann M, Erickson J, Hallberg C, et al. (2009). Improvement of psychic and somatic symptoms in adult patients with generalized anxiety disorder: examination from a duloxetine, venlafaxine extended-release and placebo-controlled trial. Psychol Med 39:267-276.
26. Nierenberg AA, Greist JH, Mallinckrodt CH, Prakash A, Sambunaris A, Tollefson GD, et al. (2007). Duloxetine versus escitalopram and placebo in the treatment of patients with major depressive disorder: onset of antidepres-sant action, a noninferiority study. Curr Med Res Opin 23:401-416. (Pubitemid 46333388)
27. Ormel J, Oldehinkel AJ, Nolen WA, Vollebergh W (2004). Psychosocial disability before, during, and after a major depressive episode: a 3-wave population-based study of state, scar, and trait effects. Arch Gen Psychiatry 61:387-392. (Pubitemid 38451548)
28. Papakostas GI, Petersen T, Denninger JW, Tossani E, Pava JA, Alpert JE, et al. (2004). Psychosocial functioning during the treatment of major depressive disorder with fluoxetine. J Clin Psychopharmacol 24:507-511. (Pubitemid 39274204)
29. Perahia DG, Wang F, Mallinckrodt CH, Walker DJ, Detke MJ (2006). Duloxetine in the treatment of major depressive disorder: a placebo- and paroxetine-controlled trial. Eur Psychiatry 21:367-378.
30. Pigott TA, Prakash A, Arnold LM, Aaronson ST, Mallinckrodt CH, Wohlreich MM (2007). Duloxetine versus escitalopram and placebo: an 8-month, double-blind trial in patients with major depressive disorder. Curr Med Res Opin 23:1303-1318. (Pubitemid 46998440)
31. Pollack MH, Endicott J, Liebowitz M, Russell J, Detke M, Spann M, et al. (2008). Examining quality of life in patients with generalized anxiety disorder: clinical relevance and response to duloxetine treatment. J Psychiatr Res 42:1042-1049.
32. Raskin A, Schulterbrandt J, Reatig N, McKeon JJ (1969). Replication of factors of psychopathology in interview, ward behavior, and self-report ratings of hospitalized depressives. J Nerv Ment Dis 148:87-98.
33. Rickels K, Rynn M, Iyengar M, Duff D (2006). Remission of generalized anxiety disorder: a review of the paroxetine clinical trials database. J Clin Psychiatry 67:41-47. (Pubitemid 43213281)
34. Rush AJ, Kraemer HC, Sackeim HA, Fava M, Trivedi MH, Frank E, et al. (2006). Report by the ACNP Task Force on response and remission in major depressive disorder. Neuropsychopharmacology 31:1841-1853.
35. Rynn M, Russell J, Erickson J, Detke MJ, Ball S, Dinkel J, et al. (2008). Efficacy and safety of duloxetine in the treatment of generalized anxiety disorder: a flexible-dose, progressive-titration, placebo-controlled trial. Depress Anxiety 25:182-189. (Pubitemid 351499896)
36. Sheehan KH, Sheehan DV (2008). Assessing treatment effects in clinical trials with the Discan metric of the Sheehan Disability Scale. Int Clin Psychopharmacol 23:70-83. (Pubitemid 351317279)
37. Sheehan DV, Harnett-Sheehan K, Raj BA (1996). The measurement of disability. Int Clin Psychopharmacol 11 (Suppl 3):89-95. (Pubitemid 26373761)
38. Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, et al. (1998). The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 59 (Suppl 20):22-33. (Pubitemid 29001829)
39. Simon GE, Revicki D, Heiligenstein J, Grothaus L, VonKorff M, Katon WJ (2000). Recovery from depression, work productivity, and health care costs among primary care patients. Gen Hosp Psychiatry 22:153-162. (Pubitemid 30394709)
40. Trivedi MH, Corey-Lisle PK, Guo Z, Lennox RD, Pikalov A, Kim E (2009). Remission, response without remission, and nonresponse in major depressive disorder: impact on functioning. Int Clin Psychopharmacol 24:133-138.
41. Weissman MM, Klerman GL, Paykel ES, Prusoff B, Hanson B (1974). Treatment effects on the social adjustment of depressed patients. Arch Gen Psychiatry 30:771-778.
42. Wittchen HU (2002). Generalized anxiety disorder: prevalence, burden, and cost to society. Depress Anxiety 16:162-171.
43. Zigmond AS, Snaith RP (1983). The hospital anxiety and depression scale. Acta Psychiatr Scand 67:361-370. (Pubitemid 13098606)